Learn about BYDUREON, a non-insulin treatment option for adults with type 2 diabetes available in the BYDUREON Pen. Find dosing and administration information for BYDUREON, including instructions for use. Learn about BYDUREON® BCise® including efficacy, safety, PK profile, and dosing, and available resources, including Important Safety Information.
|Published (Last):||16 January 2004|
|PDF File Size:||12.4 Mb|
|ePub File Size:||10.8 Mb|
|Price:||Free* [*Free Regsitration Required]|
Moderate In patients taking insulin or other antidiabetic agents, the signs and symptoms of acute metyrapone toxicity e.
Aminosalicylate sodium, Aminosalicylic acid: Epinephrine and other sympathomimetics, through stimulation of alpha- and beta- receptors, increase hepatic glucose production and glycogenolysis and apckage insulin secretion.
Conversely, patients should be closely monitored for signs of hypoglycemia when therapy with a hydantoin is discontinued. It is acceptable for the injections to be in the same body region but bdyureon injections should NOT be adjacent to each other. Prolonged exposure to stomach acid may destroy the film coating on certain medications and may result in decreased efficacy.
The agencies have not reached any new conclusions about safety risks of the incretin mimetics, although the totality of the reviewed data provides reassurance. Moderate During clinical trials of bydureoj, hypoglycemia and hyperglycemia were reported in diabetic patients receiving antidiabetic agents.
Endogenous human incretins, such as glucagon-like peptide-1 GLP-1 enhance insulin secretion after release from the gut into the systemic circulation.
Octreotide alters the balance between the counter-regulatory hormones of insulin, glucagon, and growth hormone, which packgae result in hypoglycemia or hyperglycemia. Therefore, careful monitoring of blood glucose is recommended when quinolones and antidiabetic agents are co-administered.
If a dose is missed and the next regularly scheduled dose is 1 or 2 days later, the patient should not administer the missed dose, instead they should wait until the next regularly scheduled dose. The mean terminal half-life of the injection solution Byetta is 2. This interference can lead to a loss of diabetic control, so diabetic patients should be monitored closely if these drugs are initiated.
Careful monitoring of blood glucose is recommended.
Medicine is mixed well when it appears as an even mix that is cloudy; it is okay to see air bubbles. The clinical effects of these competing mechanisms is not known.
Moderate A potential pharmacodynamic interaction exists between indapamide and antidiabetic agents, like incretin mimetics. Therefore, careful monitoring of blood glucose is recommended when quinolones and antidiabetic agents are coadministered. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent.
The main risk factors for impaired glucose tolerance due to corticosteroids are the dose of steroid and duration of treatment. Moderate Monitor patients receiving octreotide hydureon with insulin or other antidiabetic agents for changes in glycemic control and adjust doses of these medications accordingly.
Bydureon (exenatide) dose, indications, adverse effects, interactions from
Inject over 2 to 4 seconds. Visually inspect for pwckage matter and discoloration prior to administration whenever solution and container permit. Some incretin mimetics make specific recommendations to reduce the risk for interaction. Finally, both thiazides and sulfonylureas have been reported to cause photosensitivity reactions; concomitant use may increase the risk of photosensitivity. Exenatide does not impair the normal glucagon response to hypoglycemia. Some beta-blockers, particularly non-selective beta-blockers such as propranolol, have been noted to potentiate insulin-induced hypoglycemia and a delay in recovery of blood glucose to normal levels.
A green shield will pop up bydureoh the cap is removed; the green shield hides the needle. Tolbutamide has usually been considered compatible with breast-feeding.
Administer at any time of day, with or without meals. Based on animal reproduction studies, there may be risks to the fetus from exposure to exenatide during pregnancy, therefore, exenatide should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus.
Patients should be monitored for changes in glycemic control while receiving pentoxifylline in combination with antidiabetic agents. The mechanism of this interaction is not available although it may be due to delayed gastric emptying from exenatide use and the clinical impact has not been assessed.
Inhibitors of MAO type A have been shown to prolong the hypoglycemic response to insulin and oral sulfonylureas.
Decreased insulin production may occur in the pancreas due to a direct effect on pancreatic beta cells. After injection, an orange rod will appear in the window.